Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy

Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more

By Gunjan Ohri, Data Content Analyst, and Paul Bonanos, Director of Biopharma Intelligence
October 7, 2024 11:59 PM UTC

AstraZeneca is paying Hong Kong-based CSPC $100 million up front for rights to a preclinical lipid-lowering therapy with a mechanism that could complement a PCSK9 inhibitor the European pharma is already developing.

The deal will give AstraZeneca plc (LSE:AZN; NASDAQ:AZN) rights to YS2302018, a small molecule designed to prevent formation of Lp(a). Elevated levels of that form of LDL are a risk factor for cardiovascular disease...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Argenx S.E.

Astrazeneca plc

Biomarin Pharmaceutical Inc.

Camp4 Therapeutics Corp.

Cspc Pharmaceutical Group Ltd.

Curium Pharma Ltd.

DRI Healthcare Trust